May 29, 2020
Sumitovant Biopharma Announces Myovant Sciences' Additional Positive Efficacy and Cardiovascular Safety Data from Phase 3 HERO Study of Once-Daily, Oral Relugolix in Advanced Prostate Cancer and Publication in the New England Journal of Medicine
Mar 05, 2019
Enteris BioPharma Supports Endometriosis Awareness Month
Oct 24, 2018
Myovant Sciences Announces Completion of Enrollment in Phase 3 HERO Trial of Relugolix in Men with Advanced Prostate Cancer
Jun 26, 2018
Enteris BioPharma Announces Positive Results from Expanded Phase 2a Clinical Trial of Ovarest® (oral leuprolide tablet) for Endometriosis
Apr 27, 2018
AbbVie Presents New Investigational Data for Elagolix at the 2018 American College of Obstetricians and Gynecologists (ACOG) Annual Meeting
Apr 10, 2018
AbbVie and Neurocrine Biosciences Announce PDUFA Target Date of Q3 2018 for Elagolix in Endometriosis-Associated Pain
Mar 05, 2018
Julianne Hough Encourages Women to "Speak Up for Endo" during Endometriosis Awareness Month
Oct 03, 2017
Arbor Pharmaceuticals, LLC and Debiopharm International SA Announce Commercial Availability of Triptodur(TM), Triptorelin 6-month Formulation, for Treatment of Central Precocious Puberty (CPP)
Sep 07, 2017
TOLMAR Pharmaceuticals Champions Prostate Cancer Awareness Month
Sep 06, 2017
AbbVie Submits New Drug Application to U.S. FDA for Investigational Oral Treatment Elagolix for the Management of Endometriosis with Associated Pain
Jun 29, 2017
Myovant Sciences Initiates Phase 3 Clinical Program of Relugolix in Women with Endometriosis-Associated Pain